ArticleMolecular and cellular biochemistry2026
Engineered outer membrane vesicle-like nanoparticles from Lactobacillus plantarum for oral IL-22 mRNA delivery and treatment of DSS-induced colitis.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study developed an engineered Lactobacillus plantarum-derived vesicle system for oral delivery of interleukin-22 mRNA (IL-22 mRNA) and evaluated its effects on epithelial barrier repair in DSS-induced colitis. The vesicle formulation, termed P-OMVs@IL-22 m, was prepared from L. plantarum protoplasts through lysozyme treatment, ultrasonic disruption, OptiPrep density-gradient purification, and incubation-based mRNA loading. The formulation achieved an IL-22 mRNA encapsulation efficiency of 72.43 ± 6.60% and a loading capacity of 35.97 ± 3.67 ng mRNA/µg P-OMV protein. mRNA loading increased the mean particle diameter from 119 ± 3 to 389 ± 7 nm and reduced the detectable particle concentration from 7.83 ± 0.81 × 10⁹ to 6.00 ± 0.78 × 10⁹ particles/mL. P-OMVs@IL-22 m protected IL-22 mRNA from RNase-mediated degradation, remained stable under simulated gastrointestinal conditions, and exhibited pH-associated release behavior. DiR-based IVIS imaging demonstrated persistent gastrointestinal signals after oral administration. In vitro, P-OMVs@IL-22 m was taken up by intestinal epithelial cells, increased IL-22 expression, activated STAT3 signaling, and enhanced Occludin, Claudin-1, and MUC2 expression. Functional assays showed increased transepithelial electrical resistance, reduced FITC-dextran permeability, and enhanced epithelial migration and proliferation. In DSS-induced colitis, oral P-OMVs@IL-22 m mitigated weight loss, lowered disease activity index scores, preserved colon length and tissue architecture, reduced inflammatory cytokine production, and restored epithelial barrier proteins. RNA sequencing and validation analyses linked treatment to changes in lipid metabolism, proteolysis, MAPK signaling, and mTOR-related pathways. These findings establish a preclinical proof-of-concept for engineered probiotic-derived vesicles as an oral IL-22 mRNA delivery platform for epithelial barrier repair in DSS-induced colitis.
Indexed as
Identifiers
42663878What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.